Dr. Yardley on Emerging Agents in HER2-Positive Breast Cancer

Denise A. Yardley, MD
Published: Thursday, Sep 15, 2016



Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses some of the emerging agents in HER2-positive breast cancer.

One promising therapy is ONT-380 (tucatinib), which is currently under investigation in three phase I studies in combination with other anti-HER2 therapies. ONT-380 is similar to lapatinib (Tykerb), though the latter is fraught with several toxicities, says Yardley.

So far, ONT-380 has demonstrated good penetrance into the CNS, and patients treated with the agent have been stable, asymptomatic, and are generally tolerating the drug well in combination with trastuzumab (Herceptin).
SELECTED
LANGUAGE


Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses some of the emerging agents in HER2-positive breast cancer.

One promising therapy is ONT-380 (tucatinib), which is currently under investigation in three phase I studies in combination with other anti-HER2 therapies. ONT-380 is similar to lapatinib (Tykerb), though the latter is fraught with several toxicities, says Yardley.

So far, ONT-380 has demonstrated good penetrance into the CNS, and patients treated with the agent have been stable, asymptomatic, and are generally tolerating the drug well in combination with trastuzumab (Herceptin).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x